Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will present data on Iovance tumor-infiltrating lymphocyte cell therapy at the upcoming Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, to be held February 2 – 6, 2022 in Salt Lake City, Utah, and virtually.
January 7, 2022
· 5 min read